Khurshid Ahmed Khan, Ayesha Junaid, Nauman Saleem Siddiqui, Khalida Mukhtar, Saleem Siddiqui.
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
J Coll Physicians Surg Pak Jan ;18(3):176-8.

Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com